⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

DNTH News

Dianthus Therapeutics, Inc. Common Stock

Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases